A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation.
Brett Glotzbecker(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Thomas R. Spitzer(Harvard University), Jessica Bonhoff(Beth Israel Deaconess Medical Center), Carol Delaney(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Baldev Vasir(Beth Israel Deaconess Medical Center), Mary Ann Stevenson, Katharine Conway(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Nancy Giallombardo(Beth Israel Deaconess Medical Center), Kerry Wellenstein(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), Heidi Mills(Beth Israel Deaconess Medical Center), David F. McDermott(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k